US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...

Cardiac ablation has emerged as a transformative medical procedure for patients struggling with irregular heart rhythms particularly atrial fibrillation AFib By targeting and eliminating problematic a ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Antiarrhythmic drugs (AADs) are often used after ablation for atrial fibrillation (AF); the drugs employed vary, but most common are the drugs that were unsuccessful prior to ablation since it ...

Looking back, Kokomo resident Mike Beatty knew he had something as a teenager, but he couldn’t put a name to it. Whenever he’d overexert himself, he’d feel “different,” but it would go away with rest.

The following is a summary of “Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes,” published in the ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common complication being pericardial tamponade (1.1%), and a few cases of stroke (0.7%) ...

CardioFocus today announced the publication of 12-month data from a study of its pulsed field ablation (PFA) system for ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...